Biomarkers for Personalized Neoadjuvant Therapy in Triple-Negative Breast Cancer: Moving Forward

HomeRadiologyVol. 312, No. 3 PreviousNext Reviews and CommentaryEditorialBiomarkers for Personalized Neoadjuvant Therapy in Triple-Negative Breast Cancer: Moving ForwardGaiane M. Rauch Gaiane M. Rauch Author AffiliationsFrom the University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1473, Houston, TX 77030.Address correspondence to the author (email: [email protected]).Gaiane M. Rauch Published Online:Sep 3 2024https://doi.org/10.1148/radiol.242011See also the article by Ramtohul et al in this issue.MoreSectionsFull textPDF ToolsAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookXLinked In References1. Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 2017;35(10):1049–1060. MedlineGoogle Scholar2. Schmid P, Cortes J, Pusztai L, et al; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020;382(9):810–821. MedlineGoogle Scholar3. Panthi B, Mohamed RM, Adrada BE, et al. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol 2023;13:1264259. MedlineGoogle Scholar4. Abuhadra N, Sun R, Yam C, et al. Predictive roles of baseline stromal tumor-infiltrating lymphocytes and Ki-67 in pathologic complete response in an early-stage triple-negative breast cancer prospective trial. Cancers (Basel) 2023;15(13):3275. MedlineGoogle Scholar5. Ramtohul T, Lepagney V, Bonneau C, et al. Use of pretreatment perfusion MRI–based intratumoral heterogeneity to predict pathologic response of triple-negative breast cancer to neoadjuvant chemoimmunotherapy. Radiology 2024;312(3):e240575. Google Scholar6. Shi Z, Huang X, Cheng Z, et al. MRI-based quantification of intratumoral heterogeneity for predicting treatment response to neoadjuvant chemotherapy in breast cancer. Radiology 2023;308(1):e222830. Google Scholar7. Ramtohul T, Tescher C, Vaflard P, et al. Prospective evaluation of ultrafast breast MRI for predicting pathologic response after neoadjuvant therapies. Radiology 2022;305(3):565–574. Google Scholar8. Jimenez JE, Abdelhafez A, Mittendorf EA, et al. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 2022;149:110220. MedlineGoogle Scholar9. Li Y, Chen Y, Zhao R, et al. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer. Eur Radiol 2022;32(3):1676–1687. MedlineGoogle Scholar10. Zhang Y, You C, Pei Y, et al. Integration of radiogenomic features for early prediction of pathological complete response in patients with triple-negative breast cancer and identification of potential therapeutic targets. J Transl Med 2022;20(1):256. MedlineGoogle ScholarArticle HistoryReceived: July 8 2024Revision requested: July 19 2024Revision received: July 20 2024Accepted: July 22 2024Published online: Sept 03 2024 FiguresReferencesRelatedDetailsAccompanying This ArticleUse of Pretreatment Perfusion MRI–based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant ChemoimmunotherapySep 3 2024RadiologyRecommended Articles Precision Imaging: One Step Closer to Pretreatment Prediction of Breast Cancer Response to Neoadjuvant Systemic TherapyRadiology2023Volume: 308Issue: 1Multiparameter MRI and Clinical Factors for Predicting Early Response to Chemoradiotherapy in Cervical CancerRadiology: Imaging Cancer2021Volume: 3Issue: 1Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 ChallengeRadiology: Imaging Cancer2024Volume: 6Issue: 1Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant ChemotherapyRadiology2018Volume: 288Issue: 1pp. 26-35High-Resolution Photoacoustic Tomography for Early-Stage Cancer Detection and Its Clinical TranslationRadiology: Imaging Cancer2020Volume: 2Issue: 3See More RSNA Education Exhibits Cancer In PregnancyDigital Posters2021Staging Breast Cancer: A Case Based ReviewDigital Posters2022Response Evaluation Criteria in GI Cancers: What to Use and How to Measure: An Emerging Challenge in the Era of Novel Cancer TreatmentsDigital Posters2022 RSNA Case Collection Inflammatory breast cancerRSNA Case Collection2020Secondary Angiosarcoma of the BreastRSNA Case Collection2021Desmoid tumor of the male breastRSNA Case Collection2020 Vol. 312, No. 3 Metrics Altmetric Score PDF download